Bristol-Myers (BMY) Wins Ruling Blocking Generic Plavix
More News related to BMY
- Bristol-Myers Squibb and Mead Johnson Announce Amendment and Extension of Exchange Offer
- Bristol-Myers Squibb And Pfizer Announce Plans To Submit Regulatory Filing For Apixaban In Europe
- New Data on Bristol-Myers Squibb Oncology Compounds to be Featured in Oral Presentations at 51st Annual Meeting of the American Society of Hematology
- Mead Johnson Loses $13.5 Million Lawsuit to PBM Products
- Generic Erosion of Established Branded Atypical Antipsychotics Will Cause the Schizophrenia Drug Market To Decline More Than $1 Billion by 2013
More News related to SNY
- BioMed Realty (BMR) To Lease 131K Sq. Ft. From Regeneron Pharma (REGN)
- Interactive Traveling Diabetes Exhibit to Be Unveiled at Detroit Science Center
- First Commercial Order for Changda International's Thiophene from French Drug Giant
- Sanofi-aventis (SNY) Signs Licensing Agreement with Intelliject
- Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America
Bristol-Myers Squibb Co. (NYSE: BMY) and Sanofi-Aventis (NYSE: SNY) won a trial blocking generic competition on top selling blood-thinner Plavix. The court rejected Apotex\'s claim that the patent is invalid or unenforceable.
Related Categories
FDAStocks Mentioned
-0.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
